What question did this study set out to answer?

This study aimed to evaluate the effects of oral semaglutide on glycaemic control and related health markers in individuals with type 2 diabetes who are naïve to GLP-1 receptor agonists.

June 7, 2026Diabetes

1704-P: Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Patients with Type 2 Diabetes in Finland

View Full Paper

Ask AI

Bookmark

Authors

JVJERA A. VADÉN358 (Finland)MLMari LahelmaNord University LNLALLI NURMI358 (Finland)

Discussion

Member takes

Implication

Retrospective study evaluates oral semaglutide's effects on glycaemic control in adults with type 2 diabetes, suggesting significant health benefits.

Key Points

This study aimed to evaluate the effects of oral semaglutide on glycaemic control and related health markers in individuals with type 2 diabetes who are naïve to GLP-1 receptor agonists.
Identified individuals with type 2 diabetes initiating oral semaglutide from national registers.
Followed patients from April 1, 2021, to June 30, 2024, with primary endpoints at 180 and 365 days.
Examined changes in HbA1c, body weight, and various lipid profile components.
Mean HbA1c decreased from 7.9% to 6.9% at 180 days (n=1097; p<0.0001) and to 6.8% at 365 days (n=566; p<0.0001).
Body weight declined from 106 kg to 101 kg at 180 days (n=291; p<0.0001) and to 99 kg at 365 days (n=180; p<0.0001).
Significant reductions in LDL cholesterol, total cholesterol, triglycerides, and alanine aminotransferase were observed at both time points, all with p<0.0001.

Cite This Study

VADÉN et al. (2026) studied this question.

synapsesocial.com/papers/6a250ae37def13d035e1af3d https://doi.org/10.2337/db26-1704-p

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study evaluates oral semaglutide's effects on glycaemic control in adults with type 2 diabetes, suggesting significant health benefits.

1704-P: Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Patients with Type 2 Diabetes in Finland

Discussion

Member takes

Implication

Key Points

Cite This Study

1704-P: Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Patients with Type 2 Diabetes in Finland

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider